Cargando…
Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung
OBJECTIVES: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC) are both classified as pure and combined subtypes. Due to the low incidence and difficult diagnosis of combined LCNEC (C-LCNEC) and combined SCLC (C-SCLC), few studies have compared their clinical fea...
Autores principales: | Wang, Yanan, Qian, Fangfei, Chen, Ya, Yang, Zhengyu, Hu, Minjuan, Lu, Jun, Zhang, Yanwei, Zhang, Wei, Cheng, Lei, Han, Baohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493068/ https://www.ncbi.nlm.nih.gov/pubmed/34631540 http://dx.doi.org/10.3389/fonc.2021.714549 |
Ejemplares similares
-
Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy
por: Shen, Yinchen, et al.
Publicado: (2020) -
Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021) -
Pulmonary Combined Large Cell Neuroendocrine Carcinoma
por: Li, Meihui, et al.
Publicado: (2022) -
Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021) -
Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)